Impact of human serum albumin on oritavancin in vitro activity against enterococci

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Oritavancin is a lipoglycopeptide antibiotic effective against Gram-positive bacteria, including vancomycin-resistant enterococci (VRE).
• Human serum albumin (HSA) is a common component of biological fluids that can potentially affect antibiotic efficacy.
• Understanding drug-protein interactions is crucial for optimizing antimicrobial therapy.

Purpose of the Study:

• To investigate the impact of human serum albumin (HSA) on the in vitro activity of oritavancin against enterococci.
• To compare oritavancin's activity in the presence of HSA with that of other Gram-positive targeted antibiotics.

Main Methods:

• Minimum Inhibitory Concentration (MIC) assays were performed to determine the lowest drug concentration inhibiting bacterial growth.
• Time-kill assays were utilized to assess the rate of bacterial killing or inhibition over time.
• Experiments were conducted in the presence and absence of specified concentrations of human serum albumin (HSA).

Main Results:

• Oritavancin's MICs against enterococci showed a modest increase (0- to 8-fold) in the presence of HSA.
• In time-kill assays simulating peak concentrations with HSA, oritavancin demonstrated rapid bactericidal activity.
• Oritavancin exhibited superior or comparable killing kinetics to vancomycin, daptomycin, teicoplanin, and linezolid in the presence of HSA.

Conclusions:

• While HSA can slightly reduce oritavancin's MIC, it does not abrogate its potent in vitro activity against enterococci.
• Oritavancin maintains significant bactericidal efficacy in conditions simulating physiological protein binding.
• These findings support oritavancin's potential clinical utility against Gram-positive infections, even in the presence of albumin.